The C104R mutation in the TACI domain, which leads to the abnormal binding of the B-cell activating factor and a proliferation-inducing ligand, is the most frequent mutation identified in patients with CVID (37). This evidence concerns the gene TNFRSF13B and common variable immunodeficiency.